OTCMKTS:RHHBY Roche (RHHBY) Stock Price, News & Analysis $54.52 -0.97 (-1.75%) As of 08/14/2026 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartHeadlinesInsider TradesOwnershipShort InterestBuy This Stock About Roche Stock (OTCMKTS:RHHBY) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Roche alerts:Sign Up Key Stats Today's Range$54.43▼$54.8850-Day Range$49.12▼$57.4352-Week Range$39.39▼$60.85Volume1.48 million shsAverage Volume1.95 million shsMarket Capitalization$347.32 billionP/E RatioN/ADividend Yield1.78%Price Target$60.00Consensus RatingHold Company Overview Roche Holding AG is a Swiss multinational healthcare company headquartered in Basel, founded in 1896 by Fritz Hoffmann‑La Roche. The company operates primarily through two complementary divisions — Pharmaceuticals and Diagnostics — and is known for integrating drug development with diagnostic capabilities to advance personalized healthcare. In the United States and other international markets, shares trade as American Depositary Receipts under the ticker RHHBY (OTCMKTS:RHHBY). In pharmaceuticals, Roche focuses on developing and commercializing prescription medicines across therapeutic areas including oncology, immunology, infectious diseases and neuroscience, with a notable emphasis on targeted biologics and personalized therapies. The diagnostics business supplies a broad range of in vitro and molecular diagnostics, tissue‑based pathology solutions, point‑of‑care testing and diabetes care products, along with instruments and assay systems used by hospitals, laboratories and clinics to support clinical decision‑making and patient monitoring. Roche has a global footprint with operations and research facilities across Europe, the Americas and Asia, and a portfolio that combines internally developed products with offerings from affiliated biotech subsidiaries. The company emphasizes research and development and partnerships to advance precision medicine, leveraging its diagnostics expertise to support the selection and monitoring of appropriate therapies.AI Generated. May Contain Errors. Read More Roche Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks80th Percentile Overall ScoreRHHBY MarketRank™: Roche scored higher than 80% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.6 / 5Analyst RatingHold Consensus RatingRoche has received a consensus rating of Hold. The company's average rating score is 2.36, and is based on no strong buy ratings, 5 buy ratings, 5 hold ratings, and 1 sell rating.Upside PotentialRoche has a consensus price target of $60.00, representing about 10.1% upside from its current price of $54.52.Amount of Analyst CoverageRoche has only been the subject of 3 research reports in the past 90 days.Read more about Roche's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings Growth7.84% Earnings GrowthEarnings for Roche are expected to grow by 7.84% in the coming year, from $3.06 to $3.30 per share.Price to Earnings Growth RatioRoche has a PEG Ratio of 4.08. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioRoche has a P/B Ratio of 7.59. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.05% of the float of Roche has been sold short.Short Interest Ratio / Days to CoverRoche has a short interest ratio ("days to cover") of 0.78, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Roche has recently decreased by 12.02%, indicating that investor sentiment is improving significantly. Dividend1.7 / 5Dividend StrengthWeak Dividend YieldRoche pays a meaningful dividend of 1.72%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthRoche does not have a long track record of dividend growth.Dividend SustainabilityBased on earnings estimates, Roche will have a dividend payout ratio of 29.39% next year. This indicates that Roche will be able to sustain or increase its dividend.Read more about Roche's dividend. News and Social Media3.7 / 5News Sentiment0.90 News SentimentRoche has a news sentiment score of 0.90. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.65 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Roche this week, compared to 7 articles on an average week.Search Interest12 people have searched for RHHBY on MarketBeat in the last 30 days. This is an increase of 71% compared to the previous 30 days.MarketBeat Follows9 people have added Roche to their MarketBeat watchlist in the last 30 days. This is an increase of 125% compared to the previous 30 days. Company OwnershipN/AInsider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Roche insiders have not sold or bought any company stock.Percentage Held by InstitutionsRoche has minimal institutional ownership at this time.Read more about Roche's insider trading history. Receive RHHBY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Roche and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. RHHBY Stock News HeadlinesRoche Is Getting More Benefit Of The Doubt On Improving ExecutionAugust 13 at 10:41 PM | seekingalpha.comFY2026 EPS Estimates for Roche Raised by Erste Group BankAugust 13 at 2:13 AM | americanbankingnews.comA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief. It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live.August 15 at 1:00 AM | Porter & Company (Ad)Roche Stock Jumps as Morgan Stanley Sees Drug BreakoutAugust 7, 2026 | finance.yahoo.comRoche upgraded at Morgan Stanley on growth, pipeline upsideAugust 7, 2026 | msn.comRoche introduces two new Cyclospora tests amid U.S. outbreakAugust 6, 2026 | seekingalpha.comRoche expands cyclospora testing portfolio to support US public health responseAugust 6, 2026 | msn.comEvexta Bio Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate Rupitasertib in Combination with a Selective Estrogen Receptor Degrader in Advanced / Metastatic Breast CancerAugust 4, 2026 | businesswire.comSee More Headlines RHHBY Stock Analysis - Frequently Asked Questions How have RHHBY shares performed this year? Roche's stock was trading at $51.57 on January 1st, 2026. Since then, RHHBY stock has increased by 5.7% and is now trading at $54.52. Does Roche have any subsidiaries? Roche subsidiaries include Inflazome, Stratos Genomics, Promedior, Spark Therapeutics, Tusk Therapeutics, Flatiron Health, Ignyta, and more. Who are Roche's major shareholders? Top institutional investors of Roche include GAMMA Investing LLC, Puzo Michael J, Confluence Investment Management LLC and Fulton Bank N.A.. How do I buy shares of Roche? Shares of RHHBY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today8/15/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolOTCMKTS:RHHBY CIKN/A Webwww.roche.com Phone(161) 688-1111Fax41-0-61-691-9391Employees103,249Year Founded1896Price Target and Rating Average Price Target for Roche$60.00 High Price Target$63.00 Low Price Target$57.00 Potential Upside/Downside+10.1%Consensus RatingHold Rating Score (0-4)2.36 Research Coverage11 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E Ratio17.82 P/E Growth4.08Net IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.72 Current Ratio1.38 Quick Ratio1.12 Sales & Book Value Annual Sales$76.45 billion Price / Sales4.54 Cash Flow$3.54 per share Price / Cash Flow15.41 Book Value$7.18 per share Price / Book7.59Miscellaneous Outstanding Shares6,370,538,000Free FloatN/AMarket Cap$347.32 billion OptionableNot Optionable Beta0.49 Social Links The 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (OTCMKTS:RHHBY) was last updated on 8/15/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredBuy this stock todayMarc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...Chaikin Analytics | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Roche Holding AG Please log in to your account or sign up in order to add this asset to your watchlist. Share Roche With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.